title: Administration of erythropoietin to newborn rats results in diminished neutrophil production.
abstract: Very high concentrations of erythropoietin (epo), in clonogenic cultures, result in reduced production of neutrophils, and fetal progenitors are more sensitive to this effect of epo than are those of adults. However, the significance of this observation is unclear because no evidence of reduced neutrophil production has been presented following administration of recombinant epo to human or animal subjects. In the present study we injected newborn rats, beginning on the first day of life, with 20, 200, or 2,000 U epo/kg body weight, and measured serum epo concentrations after 2, 8, 24, or 48 hours. After selecting a dose that resulted in serum concentrations greater than 1,000 mU/mL (a concentration that resulted in down-modulation of neutrophil production from neonatal rat progenitors in vitro) other newborn rats were treated for 3 days with that dose (1,000 U epo/kg) or a vehicle control. Administration of epo resulted in increased hematocrits (P less than .001), reticulocyte counts (P less than .001), normoblasts/femur (P less than .05), and normoblasts/spleen (P less than .001). Recipients of epo also had more erythroid colony-forming units (CFU-E) (P less than .001) and higher CFU-E tritiated thymidine suicide rates (P less than .01) than did controls. However, femurs and spleens of epo recipients contained fewer postmitotic neutrophils (femur, P less than .01; spleen, P less than .01), proliferative neutrophils (femur, P less than .01; spleen, P less than .02), granulocyte-macrophage colony-forming units (CFU-GM) (P less than .005), and lower CFU-GM tritiated thymidine suicide rates (P less than .01). Seven and nine days after twice-daily administration of 2,000 U epo/kg, blood neutrophil concentrations had diminished (P less than .05). Thus, administration of high doses of recombinant epo to newborn rats resulted in diminished neutrophil production accompanying accelerated erythropoiesis.
authors.affiliation: Division of Human Development and Aging, University of Utah School of Medicine, Salt Lake City 84132.
authors.forename: R D
authors.initials: RD
authors.lastname: Christensen
authors.forename: K W
authors.initials: KW
authors.lastname: Liechty
authors.forename: J M
authors.initials: JM
authors.lastname: Koenig
authors.forename: K R
authors.initials: KR
authors.lastname: Schibler
authors.forename: R K
authors.initials: RK
authors.lastname: Ohls
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001835:Body Weight; D002453:Cell Cycle / Q000187:drug effects; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D005269:Femur / Q000166:cytology; D006412:Hematopoietic Stem Cells / Q000166:cytology; D007958:Leukocyte Count / Q000187:drug effects; D009504:Neutrophils / Q000166:cytology*; D051381:Rats; D011919:Rats, Inbred Strains; D013154:Spleen / Q000166:cytology
chemical_list: D004921:Erythropoietin